

Product datasheet

anti-Renal Cell Carcinoma Marker (CD205) mouse monoclonal, PN-15, purified

Short overview

Cat. No.	691716
Quantity	1 ml (100 µg/ml)
Concentration	100 µg/ml

Product description

Host	Mouse
Antibody Type	Monoclonal
Isotype	IgG2b kappa
Clone	PN-15
Immunogen	Renal cortical tissue extract
Formulation	PBS with 0.02% sodium azide
UniprotID	O60449 (Human), D3ZQK8 (Rat)
Synonym	Lymphocyte antigen 75, Ly-75, C-type lectin domain family 13 member B, DEC-205, gp200-MR6, CD antigen CD205, LY75, CD205, CLEC13B
Conjugate	Unconjugated
Purification	Affinity chromatography
Storage	2-8°C
Intended use	Research use only
Application	FACS, ICC/IF, IHC, WB
Reactivity	Horse, Human, Monkey, Rat

Applications

Flow Cytometry (FACS)	0.5-1.0 µg/million cells in 0.1 ml
Immunocytochemistry (ICC)	1:100-1:200 (0.5-1.0 µg/ml)
Immunohistochemistry (IHC) - frozen	1:25-1:50 (2-4 µg/ml)
Immunohistochemistry (IHC) - paraffin	1:25-1:50 (2-4 µg/ml; microwave treatment in 10mM citrate buffer pH 6.0 recommended)
Western Blot (WB)	1:50-1:100 (1-2 µg/ml)

Background

PN-15 reacts with a lectin receptor like glycoprotein of 200 kDa (gp200), present in proximal renal tubules and on urothelium. The antigen is carbohydrate in nature. Other normal tissues that display the antigen include breast, parathyroid glands, thymus and epididymis. Among renal carcinomas 93% of primary and 84% of metastatic carcinomas are positive. Bladder cancers are also largely positive. Other tumor types include breast cancer, teratocarcinomas and parathyroid adenomas. The antigen, also called DEC-205, was assigned to CD205 at CD workshop VII. In the immune system it can facilitate tolerance to self-antigens through uptake of apoptosis derived material by dendritic cells, which in turn present

PROGEN Biotechnik GmbH | Maaßstraße 30 | D-69123 Heidelberg


Tel.: +49 (0) 6221 8278-0 | Fax: +49 (0) 6221 8278-24 | Email: info@progen.com | Web: www.progen.com

2024 April 26 / Version: 691716/DS-230420ibg | Page 1

fragments through MHC II and MHC I, either inducing or repressing immune responses, depending on the nature of concomitant signals.

Positive control: Renal carcinoma, bladder carcinoma.

Product images



Human renal cancer